Lipidomics-based safety biomarkers for lipid-lowering treatments

Reijo Laaksonen, Minna T. Jänis, Matej Oresic

Research output: Contribution to journalArticleScientificpeer-review

19 Citations (Scopus)

Abstract

Recent data suggest that aggressive lipid-lowering treatment results in significant reductions of atherosclerotic complications, ie, strokes, heart attacks, or peripheral vascular diseases. Thus, more patients will be titrated to higher doses of statins in order to reach the aggressive targets of low-density lipoprotein— cholesterol reduction. However, aggressive treatment with high statin doses has increased the risk of statin-induced myopathy. The incidence of myopathy in cohort studies and in randomized trials has been low, supporting the good safety profile of statin drugs. However, muscle effects seem to be more frequent in clinical practice. Of all statin users, approximately 1% to 5% suffers from muscular symptoms caused by medication. This potentially reduces the compliance toward treatment and number of patients reaching their treatment targets due to withdrawal of therapy. Thus, novel biomarkers are needed for prediction or improved diagnoses of statin-induced side effects. This would potentially increase the quality of life of patients and improve treatment results. Using lipidomic analysis, we found that the plasma lipidomic changes following simvastatin treatment correlate with the muscle expression of the arachidonate 5-lipoxygenase-activating protein. Intriguingly, these results suggest that the plasma lipidomic profile may serve as a highly sensitive biomarker of statin-induced metabolic alterations in muscle and may thus allow us to identify patients who should be treated with a lower dose to prevent a possible toxicity.
Original languageEnglish
Pages (from-to)65S-68S
Number of pages31
JournalAngiology
Volume59
Issue number2 suppl.
DOIs
Publication statusPublished - 2008
MoE publication typeA1 Journal article-refereed

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Biomarkers
Lipids
Safety
Muscular Diseases
Muscles
Therapeutics
5-Lipoxygenase-Activating Proteins
Simvastatin
Peripheral Vascular Diseases
LDL Cholesterol
Compliance
Cohort Studies
Stroke
Myocardial Infarction
Quality of Life
Incidence
Pharmaceutical Preparations

Keywords

  • Statins
  • myopathy
  • lipidomics
  • biomarkers

Cite this

Laaksonen, R., Jänis, M. T., & Oresic, M. (2008). Lipidomics-based safety biomarkers for lipid-lowering treatments. Angiology, 59(2 suppl.), 65S-68S. https://doi.org/10.1177/0003319708321106
Laaksonen, Reijo ; Jänis, Minna T. ; Oresic, Matej. / Lipidomics-based safety biomarkers for lipid-lowering treatments. In: Angiology. 2008 ; Vol. 59, No. 2 suppl. pp. 65S-68S.
@article{b6ba97681f4e4607a8d7602ee0016429,
title = "Lipidomics-based safety biomarkers for lipid-lowering treatments",
abstract = "Recent data suggest that aggressive lipid-lowering treatment results in significant reductions of atherosclerotic complications, ie, strokes, heart attacks, or peripheral vascular diseases. Thus, more patients will be titrated to higher doses of statins in order to reach the aggressive targets of low-density lipoprotein— cholesterol reduction. However, aggressive treatment with high statin doses has increased the risk of statin-induced myopathy. The incidence of myopathy in cohort studies and in randomized trials has been low, supporting the good safety profile of statin drugs. However, muscle effects seem to be more frequent in clinical practice. Of all statin users, approximately 1{\%} to 5{\%} suffers from muscular symptoms caused by medication. This potentially reduces the compliance toward treatment and number of patients reaching their treatment targets due to withdrawal of therapy. Thus, novel biomarkers are needed for prediction or improved diagnoses of statin-induced side effects. This would potentially increase the quality of life of patients and improve treatment results. Using lipidomic analysis, we found that the plasma lipidomic changes following simvastatin treatment correlate with the muscle expression of the arachidonate 5-lipoxygenase-activating protein. Intriguingly, these results suggest that the plasma lipidomic profile may serve as a highly sensitive biomarker of statin-induced metabolic alterations in muscle and may thus allow us to identify patients who should be treated with a lower dose to prevent a possible toxicity.",
keywords = "Statins, myopathy, lipidomics, biomarkers",
author = "Reijo Laaksonen and J{\"a}nis, {Minna T.} and Matej Oresic",
year = "2008",
doi = "10.1177/0003319708321106",
language = "English",
volume = "59",
pages = "65S--68S",
journal = "Angiology",
issn = "0003-3197",
publisher = "SAGE Publications",
number = "2 suppl.",

}

Laaksonen, R, Jänis, MT & Oresic, M 2008, 'Lipidomics-based safety biomarkers for lipid-lowering treatments', Angiology, vol. 59, no. 2 suppl., pp. 65S-68S. https://doi.org/10.1177/0003319708321106

Lipidomics-based safety biomarkers for lipid-lowering treatments. / Laaksonen, Reijo; Jänis, Minna T.; Oresic, Matej.

In: Angiology, Vol. 59, No. 2 suppl., 2008, p. 65S-68S.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Lipidomics-based safety biomarkers for lipid-lowering treatments

AU - Laaksonen, Reijo

AU - Jänis, Minna T.

AU - Oresic, Matej

PY - 2008

Y1 - 2008

N2 - Recent data suggest that aggressive lipid-lowering treatment results in significant reductions of atherosclerotic complications, ie, strokes, heart attacks, or peripheral vascular diseases. Thus, more patients will be titrated to higher doses of statins in order to reach the aggressive targets of low-density lipoprotein— cholesterol reduction. However, aggressive treatment with high statin doses has increased the risk of statin-induced myopathy. The incidence of myopathy in cohort studies and in randomized trials has been low, supporting the good safety profile of statin drugs. However, muscle effects seem to be more frequent in clinical practice. Of all statin users, approximately 1% to 5% suffers from muscular symptoms caused by medication. This potentially reduces the compliance toward treatment and number of patients reaching their treatment targets due to withdrawal of therapy. Thus, novel biomarkers are needed for prediction or improved diagnoses of statin-induced side effects. This would potentially increase the quality of life of patients and improve treatment results. Using lipidomic analysis, we found that the plasma lipidomic changes following simvastatin treatment correlate with the muscle expression of the arachidonate 5-lipoxygenase-activating protein. Intriguingly, these results suggest that the plasma lipidomic profile may serve as a highly sensitive biomarker of statin-induced metabolic alterations in muscle and may thus allow us to identify patients who should be treated with a lower dose to prevent a possible toxicity.

AB - Recent data suggest that aggressive lipid-lowering treatment results in significant reductions of atherosclerotic complications, ie, strokes, heart attacks, or peripheral vascular diseases. Thus, more patients will be titrated to higher doses of statins in order to reach the aggressive targets of low-density lipoprotein— cholesterol reduction. However, aggressive treatment with high statin doses has increased the risk of statin-induced myopathy. The incidence of myopathy in cohort studies and in randomized trials has been low, supporting the good safety profile of statin drugs. However, muscle effects seem to be more frequent in clinical practice. Of all statin users, approximately 1% to 5% suffers from muscular symptoms caused by medication. This potentially reduces the compliance toward treatment and number of patients reaching their treatment targets due to withdrawal of therapy. Thus, novel biomarkers are needed for prediction or improved diagnoses of statin-induced side effects. This would potentially increase the quality of life of patients and improve treatment results. Using lipidomic analysis, we found that the plasma lipidomic changes following simvastatin treatment correlate with the muscle expression of the arachidonate 5-lipoxygenase-activating protein. Intriguingly, these results suggest that the plasma lipidomic profile may serve as a highly sensitive biomarker of statin-induced metabolic alterations in muscle and may thus allow us to identify patients who should be treated with a lower dose to prevent a possible toxicity.

KW - Statins

KW - myopathy

KW - lipidomics

KW - biomarkers

U2 - 10.1177/0003319708321106

DO - 10.1177/0003319708321106

M3 - Article

VL - 59

SP - 65S-68S

JO - Angiology

JF - Angiology

SN - 0003-3197

IS - 2 suppl.

ER -